C12Y 101/01053
3-alpha -hydroxysteroid dehydrogenase
Official title: 3-Alpha (or 20-beta)-hydroxysteroid dehydrogenase (1.1.1.53)
C12Y101/01053 (3-alpha -hydroxysteroid dehydrogenase) appears on 6 US grants and 4 published applications in this corpus.
Search patents in C12Y- Granted patents
- 6
- Published applications
- 4
- Assignees
- 7
- Inventors
- 12
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids19 May 2026US 12,630,853 B2Euroapi France
- Intracellular amyloid-beta binding (ERAB) polypeptide-related assays7 Feb 2006US 6,994,974 B1The Trustees of Columbia University in the City of New York
- Process for oxidation of steroids and genetically engineered cells used therein14 Oct 2003US 6,632,633 B1Aventis Pharma S. A.
- Intracellular amyloid-beta peptide binding (ERAB) polypeptide31 Jul 2001US 6,268,479 B1The Trustees of Columbia University in the City of New York
- Process for oxidation of steroids and genetically engineered cells used therein9 Jan 2001US 6,171,836 B2Hoechst Marion Roussel, Inc.
- Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids5 May 2022US 2022/0136029 A1Sanofi
- Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions4 Jan 2007US 2007/0004624 A1
- Process for oxidation of steroids and genetically engineered cells used therein8 Apr 2004US 2004/0067579 A1Aventis Pharma S.A.
- Process for oxidation of steroids and genetically engineered cells used therein12 Jun 2003US 2003/0108982 A1Aventis Pharma S.A.
Most cited
By later US patents
- Intracellular amyloid-beta peptide binding (ERAB) polypeptide16US 6,268,479 B1The Trustees of Columbia University in the City of New York · 2001
- Intracellular amyloid-beta binding (ERAB) polypeptide-related assays5US 6,994,974 B1The Trustees of Columbia University in the City of New York · 2006
- Expression cassette operable in a recombinant host2US 5,869,283 ARoussel Uclaf · 1999
- Process for oxidation of steroids and genetically engineered cells used therein2US 6,632,633 B1Aventis Pharma S. A. · 2003